Efficacy and tolerability of trabectedin in elderly patients with sarcoma: subgroup analysis from a phase III, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma

BACKGROUND: Treatment options for soft tissue sarcoma (STS) patients aged ≥65 years (elderly) can be limited by concerns regarding the increased risk of toxicity associated with standard systemic therapies. Trabectedin has demonstrated improved disease control in a phase III trial (ET743-SAR-3007) o...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Ann Oncol
Главные авторы: Jones, R L, Demetri, G D, Schuetze, S M, Milhem, M, Elias, A, Van Tine, B A, Hamm, J, McCarthy, S, Wang, G, Parekh, T, Knoblauch, R, Hensley, M L, Maki, R G, Patel, S, von Mehren, M
Формат: Artigo
Язык:Inglês
Опубликовано: Oxford University Press 2018
Предметы:
Original Articles
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6454486/
https://ncbi.nlm.nih.gov/pubmed/30084934
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdy253
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы